Long-term outcomes of apixaban as main anticoagulant in patients with HeartMate 3 left ventricular assist devices.

Aims: HeartMate 3 (HM3) left ventricular assist devices (LVADs) offer improved haemocompatibility-related outcomes for end-stage heart failure patients, facilitating the exploration of alternative anticoagulation therapies beyond warfarin. This study presents a long-term evaluation of thrombotic and bleeding outcomes in HM3 LVAD patients transitioned from warfarin to apixaban.

Methods: We retrospectively identified HM3 LVAD patients at our single centre who transitioned from warfarin to apixaban.